Project Grant HT9425261E327
Award Date 7/1/26
Completion Date 6/30/28
Dollars Obligated $529K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded UCLA a $799,999 Project Grant effective May 1, 2026, through April 30, 2030, under the Military Medical Research and Development program (CFDA 12.420). The project, titled "From H & E to HRD: Linking Morphometry, Clinical, and Molecular Data for Drug Response Prediction," supports biomedical research designed to advance medical solutions for Service Members and the military population. This award represents...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $7.999 million to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420) on August 1, 2026, for a Phase 1 single-blind, placebo-controlled, dose escalation study evaluating the safety of AD-NP1, a humanized monoclonal antibody targeting human enpp1 (ectonucleotide pyrophosphatase/phosphodiesterase 1). The project, to be conducted at UCLA's Los Angeles...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded the University of California, Los Angeles a $1.70 million Project Grant on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "The 3D Multiomic Determinants of Prostate Cancer Lethality." The three-year project, with completion targeted for May 31, 2029, will be performed at UCLA's Los Angeles campus and is expected to deliver investigator-initiated biomedical...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $235,476 project grant to the University of California, Los Angeles (UCLA) Office of Research Administration on November 1, 2025, to develop new cell-mediated immunotherapeutic strategies for neuroendocrine prostate cancer. The two-year award, which concludes October 31, 2027, is funded under the Military Medical Research and Development program (CFDA 12.420) and will be conducted at UCLA's Los Angeles, California facility....
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $590,625 Project Grant to the University of California, Los Angeles (UCLA) effective September 1, 2025, through August 31, 2028, under the Military Medical Research and Development program (CFDA 12.420). The award supports a pilot study investigating dual immunotherapy targeting programmed cell death protein 1 (PD-1) and CD73 in combination with chemotherapy for patients with pancreatic adenocarcinoma, with particular focus on...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded a $2,076,089 Project Grant to the University of California, Los Angeles (UCLA) beginning September 1, 2026 and concluding August 31, 2030 under the Military Medical Research and Development program (CFDA 12.420). The project, titled "Defining an Error-Free DNA Repair Signature as a Predictive Marker for Lethal Prostate Cancer," supports basic and applied biomedical research conducted at UCLA's Los Angeles,...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles a $1.75 million Project Grant on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support a three-year research initiative titled "Deconstructing AAV-Associated Liver Toxicity: Biomarkers and Immune Insights to Enable Safer Gene Therapies." The project, which will be performed in Los Angeles, California, and is scheduled for...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded $350,000 to the University of California, Los Angeles (UCLA) Office of Research Administration on September 30, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop a polylactic acid (PLA)-based, immunohistochemistry (IHC)-compatible functional assay for detecting homologous recombination deficiency in ovarian cancer. The project will be performed in Los Angeles, California, with an ultimate...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded UCLA a $2.16M Project Grant on September 30, 2025, under the Military Medical Research and Development program (CFDA 12.420) to conduct research on cerebellar neuromodulation to reduce cognitive dysfunction after multiple subconcussive impacts. The four-year project, scheduled for completion on September 29, 2029, will be performed at UCLA's Los Angeles campus through the Office of Research Administration. This award supports...
- Federal Grant Award Summary The University of California, Los Angeles (UCLA) received a $551,216 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2027. The grant funds research to elucidate the functional role of PPP1R1B-lncRNA in myocyte repair in Duchenne muscular dystrophy (DMD). This research initiative represents a hypothesis-driven investigation into therapeutic...